ARS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.7 USD | +1.16% |
|
+2.35% | +58.76% |
| Apr. 18 | ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing | MT |
| Apr. 18 | ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 799.9 | 526.1 | 843 | - | - |
| Enterprise Value (EV) 1 | 525.5 | 526.1 | 701.6 | 698.7 | 619.1 |
| P/E ratio | -9.8 x | -9.61 x | -14.3 x | -25.3 x | 22 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 608 x | 17,535 x | 152 x | 9.87 x | 3.98 x |
| EV / Revenue | 399 x | 17,535 x | 127 x | 8.18 x | 2.92 x |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 93,770 | 95,997 | 96,894 | - | - |
| Reference price 2 | 8.530 | 5.480 | 8.700 | 8.700 | 8.700 |
| Announcement Date | 3/23/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 1.316 | 0.03 | 5.543 | 85.45 | 211.9 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | - | -35.52 | -67.52 | -64.94 | -27.41 | 67.76 |
| Operating Margin | - | -2,698.78% | -225,066.67% | -1,171.6% | -32.08% | 31.97% |
| Earnings before Tax (EBT) 1 | - | -34.68 | -54.36 | -55.37 | -20.85 | 79.52 |
| Net income 1 | -20.24 | -34.68 | -54.36 | -59.23 | -35.04 | 39.96 |
| Net margin | - | -2,635.41% | -181,216.67% | -1,068.61% | -41% | 18.86% |
| EPS 2 | -0.8300 | -0.8700 | -0.5700 | -0.6100 | -0.3433 | 0.3950 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 10/6/22 | 3/23/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.02 | 0.01 | - | - | - | - | 1 | 4.34 | 2.8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -15.44 | -18.71 | -20.6 | -17.98 | -57.29 | -10.23 | -11.15 | -18.84 | -24.73 | - |
| Operating Margin | - | -93,565% | -206,030% | - | - | - | - | -1,883.6% | -569.84% | - |
| Earnings before Tax (EBT) 1 | -14.43 | -14.96 | -17.37 | -14.87 | -7.168 | -7.486 | -8.475 | -16.69 | -22.72 | - |
| Net income 1 | -14.43 | -14.96 | -17.37 | -14.87 | -7.168 | -10.44 | -12.54 | -16.19 | -20.06 | - |
| Net margin | - | -74,805% | -173,700% | - | - | - | - | -1,619.3% | -462.2% | - |
| EPS 2 | -0.0900 | -0.1600 | -0.1800 | -0.1600 | -0.0700 | -0.1100 | -0.1300 | -0.1650 | -0.2050 | -0.1900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/23/23 | 5/15/23 | 8/10/23 | 11/9/23 | 3/21/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 274 | - | 141 | 144 | 224 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | 0.2 | - | - | - | - |
| Capex / Sales | - | 15.12% | - | - | - | - |
| Announcement Date | 10/6/22 | 3/23/23 | 3/21/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.6
USD
Average target price
19
USD
Spread / Average Target
+120.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +58.76% | 833M | |
| +0.17% | 42.86B | |
| +10.92% | 42.74B | |
| +44.30% | 41.36B | |
| -6.20% | 27.68B | |
| +5.23% | 25.15B | |
| -24.79% | 18.63B | |
| +26.69% | 12.37B | |
| -3.13% | 11.92B | |
| +6.57% | 11.21B |
- Stock Market
- Equities
- SPRY Stock
- Financials ARS Pharmaceuticals, Inc.
